

PragmaClin Research US Inc.

\$15,750,000 Seed Round – Private Placement

Next-Generation Parkinson's Disease Management

Disclosure:

This document is for the confidential use of those parties to whom it was transmitted by the advisors mentioned only. This document is not to be misconstrued as an offer to sell or buy securities of any kind. No representation or warranty, expressed or implied is made as to the accuracy, or completeness of the contents herein.

The Principals of Atoll Financial Group are registered representatives of BA Securities, LLC. Securities and Investment Banking Services are offered through BA Securities, LLC Member FINRA, SIPC. Atoll Financial Group and BA Securities, LLC are separate and unaffiliated entities.

Proprietary and Confidential - Not for distribution

Regulatory Disclosure

This Confidential Memorandum ("Memorandum") has been prepared based on information supplied by the management of the Company. This information is being furnished through Atoll Financial Group and B A Securities, L L C solely for use by the recipient in consideration of an expressed potential interest in the financing presented herein. No person has been authorized to make any representations with respect to the Company and no person has been authorized to present information with respect to the Company, other than the advisors listed herein. This Memorandum may not be reproduced or used for any other purpose. This Memorandum includes highly confidential and proprietary information and is delivered on the express condition that such information will not be disclosed to anyone except persons in the recipient organization who have a need to know, solely for purposes of considering whether to explore a transaction. No copies of this Memorandum shall be made or retained without the prior written consent of the Company, Atoll Financial Group, and BA Securities, LLC. The recipient also agrees to comply with the restrictions set forth in the confidentiality agreement executed with the Company, pursuant to which the Company has agreed to provide this Memorandum to the recipient.

The sole purpose of this Memorandum is to assist the recipient in deciding whether to proceed with further investigation of the Company. It is not an offer to sell or a solicitation of an offer to buy securities or assets but is solely for purposes of providing information regarding the Company. All information regarding the Company is based upon information and other sources deemed to be reliable, however, while the information contained herein is believed to be accurate at the time this Memorandum was prepared, the Company, Atoll Financial Group, and BA Securities, L L C expressly disclaim any and all liability for omissions or misstatements in this Memorandum, or for any other written or oral communication or representation transmitted to any party in the course of its evaluation of and/or transaction with the Company, except for those contained in a definitive agreement executed by all necessary parties. Each inquirer is encouraged to make an independent determination of relevant facts.

The Company reserves the right to request the return of this Memorandum along with any extract or copy thereof at any time. The Company expressly reserves the right, without giving reasons therefore, at any time and in any respect, to amend or terminate the transaction process, to terminate discussions with any or all prospective partners, to reject any or all proposals, or to negotiate with parties simultaneously with respect to a transaction involving the Company. Any distribution of this Memorandum to any person other than the recipient, in whole or in part, or the divulgence of any of its contents (other than to the recipient's tax and financial advisers, attorney and accountants, who will likewise be required to maintain the confidentiality of this Memorandum) is unauthorized. Any such disclosure of the tax treatment, tax structure and other tax-related materials shall not be made for the purpose of offering to such person an opportunity to participate in the transaction process or soliciting an offer to participate in such transaction process.

This document contains forward-looking statements that involve a number of risks and uncertainties such as statements of the Company's plans, objectives, expectations and intentions. Actual results may differ materially as a result of risks faced by the Company. These risks include, but are not limited to, general economic conditions, conditions affecting the relevant industry, management's actual ability to execute its plans and conditions affecting the general technology industry. The financial projections presented in this Memorandum represent the subjective views of the management of the Company and management's current estimates of future performance based on various assumptions which management believes are reasonable, but which may or may not prove to be correct. There can be no assurance that management's views are accurate or that management's projections will be realized.

The Principals of Atoll Financial Group are registered representatives of BA Securities, LLC. Securities and Investment Banking Services are offered through B A Securities, L L C Member FINRA, and SIPC. Atoll Financial Group and B A Securities, L L C are separate and unaffiliated entities.

The information in this presentation is based upon the Company's estimates and reflects prevailing conditions and our views as of this date, all of which are accordingly subject to change. In preparing this proposal, we have relied upon and assumed, without independent verification, the accuracy and completeness of information available from public sources and provided to us by the Company. In addition, our analyses are not and do not purport to be appraisals of the assets, stock, or business of the Company or any other entity. Neither Atoll Financial Group, Inc., nor B A Securities, LLC, make any representations as to the actual terms, which may be received by the Company in connection with an investment or other transaction nor the legal, tax or accounting effects of consummating a transaction or investment.

Atoll Financial Group, Inc., and B A Securities, L L C do not render legal or tax advice, and the information contained in this communication should not be regarded as such. This presentation is for informational purposes only and does not constitute an offer, invitation or recommendation to buy, sell, subscribe for or issue any securities or a solicitation of any such offer or invitation and shall not form the basis of any contract with either Atoll Financial Group, Inc., or B A Securities, LLC. Atoll Financial Group, Inc., and B A Securities, L L C are separate and unaffiliated entities.

Proprietary and Confidential - Not for distribution

Forward Looking Statements

Forward Looking Statement

No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein. This presentation includes

certain “forward-looking statements”. All statements other than statements of historical fact included in this presentation, including without limitation statements regarding the potential business growth of the companies highlighted herein are forward-looking statements that involve various risks and uncertainties. The revenue forecasts contained herein are only estimates and no assurance can be given that any particular level of revenue will be realized or that an identified asset to be acquired, business strategy, or technology in development and to be deployed, will ever qualify as commercially viable, economical or profitable. In addition, the level and quantity of the ultimate results described may differ from the ones achieved and the difference may be material. The estimated results and projections described herein should not be interpreted as assurances of the profitability of future operations.

There can be no assurance that forward-looking statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company expectations include, among others, risks related to the actual results of current technology commercialization activities, conclusions of economic evaluations and changes in projected parameters as plans continue to be refined. Although the Company has attempted to identify important factors that could cause actual results to differ materially, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate as actual results, and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements.

Future-Oriented Financial Statements

To the extent any forward-looking information in this presentation constitutes “future-oriented financial information” or “financial outlooks” within the meaning of applicable securities laws, such information is being provided to demonstrate the anticipated market penetration and the reader is cautioned that this information may not be appropriate for any other purpose and the reader should not place undue reliance on such future-oriented financial information and financial outlooks. Future-oriented financial information and financial outlooks, as with forward-looking information generally, are, without limitation, based on the assumptions and subject to certain risks including, without limitation, those set out above under the heading “Forward Looking Statements”. The Company’s actual financial position and results of operations may differ materially from current expectations and, as a result, the Company’s revenue and expenses may differ materially from the revenue and expenses profiles provided in this presentation. Such information is presented for illustrative purposes only and may not be an indication of the Company’s actual financial position or results of operations.

Atoll Financial Group, Inc., and B A Securities, L L C do not render legal or tax advice, and the information contained in this communication should not be regarded as such. This presentation is for informational purposes only and does not constitute an offer, invitation or recommendation to buy, sell, subscribe for or issue any securities or a solicitation of any such offer or invitation and shall not form the basis of any contract with either Atoll Financial Group, Inc., or B A Securities, LLC. Atoll Financial Group, Inc., and B A Securities, L L C are separate and unaffiliated entities.

Proprietary and Confidential - Not for distribution

Infrequent Monitoring & Limited Access Drive High Costs for Parkinson’s Disease Patients and Hospitals

CHALLENGES

Infrequent Monitoring

PD patients receive 1-2 evaluations per year, leaving gaps in treatment adjustments as symptoms can vary each day.

Lack of Accessibility

Underserved areas face barriers to accessing specialist care: 40% PD patients did not see a neurologist at all during the year¹

Misdiagnosed cases

Current PD assessment scales (MDS-UPDRS) are subjective, which introduces variability and potential bias.

IMPACT

More Complications

Delayed symptom detection leads to complications, with \$5,000/year per patient spent on avoidable hospitalizations²

Delayed Evaluations

To increase in-clinic evaluation, patients spend an additional \$500–\$1,000/year per patient in travel-related expenses.

Wasted Resource

Misdiagnoses contribute to \$2,000–\$5,000/year per patient in unnecessary treatments and wasted resources.

1 Pearson, 2023 2. The Lewin Group, 2019, Jerry et al, 2022, Fujita et al, 2021

PRIMS® Delivers High-Accuracy, Objective Assessments for Parkinson’s Disease

11 minutes

Objective Scoring

Instead of the typical 30 minute in-clinic evaluations, PRIMS® delivers fast, comprehensive assessments.

85% Accuracy*

Outperforming traditional subjective assessments with high and improving accuracy, ensuring reliable, data-driven decision-making.

Proprietary and Confidential - Not for distribution

PragmaClin has Intellectual Property for the PRIMS machine learning scoring algorithm.

Effortless Monitoring with 35-Symptom Tracking and Personalized Reports with PRIMS®

No Wearables Required

- 35 symptoms tracked
- Customizable Reports

Simplifies the user experience by eliminating the need for wearable devices, reducing barriers to adoption.

PRIMS® objectively tracks 35 motor and non-motor symptoms using AI-powered analysis (including tremor, bradykinesia (slowness), rigidity, postural instability, freezing of gait, gait dysfunction, (cramped/small writing), reduced facial movement (hypomimia), involuntary and erratic movements (dyskinesia)).

ASSESSMENT HISTORY

PRIMS Assessment	21
COGNITIVE IMPAIRMENT	1022

Have You had trouble with memory or paying attention?

Welcome Back; John!

Survey

Facial Expression	Complete Survey	
Assessing Fano Irmor	ASSESSMENT HISTORY	
View Survey History	PRIMS Assessment	
24, 2022	Vobling	
PRIMS Assessment	2.0	
Assessments	Tremor	cft
Aug 7, 2022	PRIMS Assessment	
Facial	Coming Soon	

Speech Facial Expression	Fingerap? Richc Complete Survey	
Aug 10, 2022	PRIMS Assessment	
2022	Resources	
PRIMS Assessment	2.5	

Upper Limb

Dexterity Left	Dexterity Right
Stoninger Tapping	3 coming Soon
Tremor	Tremor
Left	Right

Proprietary and Confidential - Not for distribution

PragmaClin has Intellectual Property for the PRIMS machine learning scoring algorithm.

PRIMS® improves and optimizes care delivery

For patients

- Non-invasive & at-home monitoring
- No wearables required, reducing patient burden and increasing adherence

Optimized medication & therapy adjustments

- Real-time symptom tracking enables precise treatment adjustments, minimizing “on-off” fluctuations
- Reduced hospitalizations & falls
- Predictive analytics help prevent complications, improving patient safety and independence¹

For providers

Accurate assessment ratings

PRIMS® delivers precise assessment ratings through advanced algorithms and real-time data analysis, providing accurate insights for better decision-making

Enhanced efficiency for clinicians

Automates symptom tracking and reporting, reducing assessment time by up to 50%²

Significant healthcare cost reduction

Across 1 million PD patients, PRIMS could save the healthcare system an estimated \$1–\$2 billion annually

Footnotes

- Fujita et al, 2021
- Dorsey et al, 2011

A Multi-Billion Dollar Opportunity to Transform Parkinson’s Care

10 M PD patients worldwide

Including 1 M PD patients and 60,000+ new cases/year in the US.

The global PD market is projected to reach \$11 billion by 2030

Global telehealth market reaches \$455 billion by 2030

Increasing demand for remote healthcare solutions with more tools enabling accurate remote monitoring and follow-ups

Market Segmentation (USA)

300	Specialty clinics and neurology centers
5,000	Community hospitals
50,000	Physical therapy rehabilitation centers

Proprietary and Confidential - Not for distribution

Competition

Company	Main Product/Tech	AI-based	Clinical Validation Required	Comprehensive Tracking across 35 PD Symptoms	No Wearables
PragmaClin	PRIMS system uses AI-driven video monitoring and assessment to track and measure 35 PD symptoms				
Rune Labs (Strive PD)	Apple Watch application to detect and measure motor symptoms (eg tremors) and sends to clinicians				
Roche (Roche PD)	Roche watch collects motor symptoms and sends to clinicians				
ParkinSense (PD Watch)	PD watch collects motor symptoms and sends to clinicians				
PDMonitor	Five wearable monitoring devices to detect PD symptoms				
H2O Therapeutics (Parky App)	Apple Watch application to detect and measure motor symptoms (eg tremors) and sends to clinicians				
Great Lakes Neurotechnology	Various monitoring devices (KinesiaU watch, KinesiaOne and Kinesia360 wearable motion sensors) to detect and measure motor symptoms	X	X	X	
Global Kinetics (PKG Health)	PKG watch collects motor symptoms and sends to clinicians				
Machine Medicine	Kelvin platform uses advanced pose estimation to objectively track patient movements for research only	X	X		
Mon4T	Smartphone-based movement tracking of PD symptoms				

Proprietary and Confidential - Not for distribution

Competition

Technological Advancement

1	PragmaClin
	AI capabilities paired with remote monitoring effectiveness
	rune labs
J[Monat
PKG	1
HEALTA	
Clinical Validation	Ji
	Parky
6	R EAT LAKES
1	NEUROTECHNOLOGIES
	PARKIN SENSB MACHINE MEDICINE
Market Fit	<
	pdmonitor
	Effectively fits neurologist and PD patient needs

Market Fit (Patient and Provider Needs)

Proprietary and Confidential - Not for distribution

Go-To-Market

Stage 1	Stage 2	Stage 3
• Large Hospitals: Integrated Delivery Networks (IDNs) • Neurologists and movement disorder specialists • Parkinson's care clinics and hospitals	• Community Hospitals • Rehab centers and PT centers • Care facilities for elderly	• Pharmaceutical companies conducting clinical trials • Deployment in trial sites globally • Patients?

Mid 2026 2027 2028 2029 2030

Early Adoption in Canada and US (Year 1-2)

Expansion to Europe and Asia (Year 3-4)

Scale to other neurological disorders (Year 5+): Multiple Sclerosis, Huntington's Disease, Essential Tremor, etc

Proprietary and Confidential - Not for distribution

Financial Data

Fiscal years ending June 30	Fiscal Year 2025 (USD)	Fiscal Year 2026 (USD)	Fiscal Year 2027 (USD)	Fiscal Year 2028 (USD)	Fiscal Year 2029 (USD)
Revenues	\$ -	\$ -	\$ 15.3	\$ 21.6	\$ 36.0
EBITDA	\$ (0.6)	\$ (8.3)	\$ 2.5	\$ 10.2	\$ 22.7
Net income	\$ (0.5)	\$ (8.3)	\$ 1.7	\$ 7.1	\$ 15.9

CAPEX (R&D) Fiscal years ending June 30 Free Cash Flow	\$ 0.4 Fiscal Year 2025 (USD) \$ 0.0	\$ 5.7 Fiscal Year 2026 (USD) \$ (0.6)	\$ 5.5 Fiscal Year 2027 (USD) \$ (8.9)	\$ 2.0 Fiscal Year 2028 (USD) \$ (0.6)	\$ 2.0 Fiscal Year 2029 (USD) \$ 7.2
---	---	---	---	---	---

Memo:

Gross Margin	N/A	N/A	96.2%	94.6%	96.2%
EBITDA Margin	N/A	N/A	16.3%	47.2%	63.2%
Net Margin	N/A	N/A	11.4%	33.0%	44.3%

Proprietary and Confidential - Not for distribution

Team

Bronwyn Bridges	Colin Taylor	Aleksandra Podlewska	Thomas Arena
CEO and Cofounder	CTO	CSO	
Ravideep Singh	Gerard Noseworthy	Ahmed Julkernain	Josh White
Software Developer/AI Lead	Software Team Lead	Software Developer	Software Developer
Saba Shahbaz	Madison Squires	Mandy Woodland	Maggie Clarkin
Product Lead	Researcher	Operations Manager	Controller

Proprietary and Confidential - Not for distribution

Key Milestones

	2020-2022	2023	2024	2025
2020	- Incorporated			

- Patented
- Trademarked |- Q1: \$1M Project approved by Provincial and Federal agencies |- Raising.. || |2022|- Q4: Completed data collection study with King’s College Dubai |- Q2: Funded by Provincial and Federal Agencies |- Total grants raised
- \$78,000 USD
- \$2.8M CAD ||

Proprietary and Confidential - Not for distribution

Supporters

World Class Supporters

Partners

ICTA CANADIAN TECHNOLOGY ACCELERATORS	plucludPLApuk
Northeastern University	NL BALANCE & DIZZINESS CENTRE
The Roux Institute	genesis

AGFW-H ICATA CANADIAN TECHNOLOGY ACCELERATORS	vietys University plucludPLApuk
Ontario Institute	Canada & technology and aging network
BRAIN ONTARIEN	opportunit"8
Institute du Cerveau	Newfoundland & Labrador
University College Cork, Ireland	LONDON
Colaiste na hollscoile Corcaigh	
Entrepreneurship	CENTRE FOR AGING
World Cup	+BRAIN HEALTH
ASEAN	INNOVATION
RCCRC	MaineHealth

Powered by Baycrest

Proprietary and Confidential - Not for distribution

Transaction at a Glance

Chart Data - Post-Money Primary Ownership Stake

Use of Proceeds (MM USD)	Amount		Ownership Stake
Working Capital	4,358,900	Co-Founder 1	28.06%
Pipeline Development & Implementation	3,208,600		
Integration of Next Condition	2,913,000	Co-Founder 2	28.06%
Regulatory Compliance & Approvals	2,527,500	Key Employee 3	8.02%
Hardware Design & Development	2,112,000		
Transaction Fees	630,000	New Investors	35.07%
Total Use of Proceeds	15,750,000	Other	0.80%

Return Analysis

	IRR	2029 P/E Multiple		Cash Return (x)	2029 P/E Multiple		
		10.0	12.0	14.0			
Exit Year 2027	37.70%	43.18%	48.10%	Exit Year 2027	1.9	2.1	2.2
Exit Year 2028	37.70%	43.18%	48.10%	Exit Year 2028	2.6	2.9	3.2
Exit Year 2029	37.70%	43.18%	48.10%	Exit Year 2029	3.6	4.2	4.8

Proprietary and Confidential - Not for distribution

ADVISORY TEAM

JJ Carrasco Managing Partner and Founder jjca@atollfinancial.com M (240) 417-8927 W (202) 706-9960 Jonathan Hakala Managing Director of Capital Markets jonathanh@atollfinancial.com M (917) 687-6877 W (202) 706-9960 Dr. Sergio Botero Lead Advisor Bioengineering sergiob@atollfinancial.com M (646) 421-8515 W (202) 706-9960 Bring your vision. We'll find the way.

www.atollfinancial.com

Proprietary and Confidential - Not for distribution